Expert opinion on the prescription practices of silodosin and combination therapies in the management of benign prostatic hyperplasia in Indian settings
Abstract
Aim: To assess the prescription practices and preferences of clinicians regarding the use of silodosin and combination therapies for managing benign prostatic hyperplasia (BPH) in routine clinical settings in India. Methodology: A cross-sectional study was conducted among clinicians and used a 23-item multiple-response questionnaire. The survey explored various aspects of BPH management, including diagnostic practices, patient demographics, treatment preferences, combination therapy approaches, acute urinary retention management, lifestyle modifications, medication adherence factors, common symptoms and comorbidities, medication side effects, and patient education methods. Results: The study involved 60 clinicians, with the majority (48.33%) diagnosing between 11 and 20 patients with BPH per week. In the management of BPH, most clinicians preferred using silodosin either in combination therapy (78%) or as a standalone treatment (78%), and as an alpha-blocker commonly prescribed for ureteric stones (62%) and nocturia (88%). A significant proportion of the clinicians (85%) reported faster action as the most common reason to prescribe silodosin. The majority of clinicians (63%) preferred silodosin as the drug of choice in patients with trials without the catheter. More than half of the respondents (55%) reported that 25-50% of the patients adhere to silodosin therapy in a year. According to 38% and 37% of clinicians, 21-30% and 11-20% of patients, respectively, switch from…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 11 participants or records.
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.